NCT07265622RecruitingPhase 1
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of 7MW4911 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.1 site in 1 country200 target enrollmentStarted: November 12, 2025Last updated:
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Incidence and rates of adverse events
Study Overview
Brief Summary
This is the first-in-human study of 7MW4911 in Chinese patients, to investigate its prelimary safety and efficacy in patients with Advanced Solid Tumors.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Life expectancy ≥ 3 months.
- •Participants with pathologically (histologically or cytologically) confirmed advanced solid tumors.
- •Disease progression after the most recent treatment regimen.
- •At least one measurable lesion according to RECIST v1.
- •Provision of archival tumor tissue or fresh biopsy.
- •Adequte hematologic funciton, liver function and renal function.
- •Comply with contraceptive requirements.
Exclusion Criteria
- •Other concurrent malignancy in the recent 3 years except for adequately treated carcinoma in situ.
- •Active, untreated or symptomatic CNS metastasis.
- •Effusions that require frequent drainage.
- •Patients with active autoimmune disease, except for type I diabetes, hypothyroidism and other autoimmune disease that does not require systemic treatment.
- •Severe respiratory disease that required hospitalization in the last 28 days.
- •Significant and uncontrolled cardiovascular disease or events in the 6 months prior to study drug administration.
- •Poorly controlled blood glucose with fasting blood glucose above 10 mmol/L.
- •Recipient of allogeneic stem cell transplant or organ transplant
- •Active HIV or hepatitis B/C infection. Infection requiring systemic IV in the 14 days prior to study drug administration.
- •Experiencing toxicities from prior anti-cancer therapies that have not recovered to CTCAE grade 0-1, except for alopecia and endocrinopathies.
- •Prohibited treatment and treatment that requires washout period: (1) Has received another Topo-I payload ADC, and/or another CDH17 targeting therapy. (2) Received other cancer therapy within 5 half-lives or 21 days prior to study drug administration. (3) Major surgeries within 28 days prior to study drug administration. (4) Investigational therapy within 28 days prior to study drug administration. (5) Systemic treatment with immunosuppressive agents within 28 days prior to first drug administration. Physiological dose of glucocorticoid, topical glucocorticoid are allowed. (6) Use of strong CYP3A4 inhibitor or inducer.
- •Known hypersensitivity to 7MW4911 or components of the formulation.
- •Abuse of narcotic or psychoactive drugs.
- •Pregnant or breastfeeding women.
- •Other circumstances or conditions where the investigator judges to be unsuitable for study.
Arms & Interventions
7MW4911
Experimental
Intervention: 7MW4911 (Drug)
Outcomes
Primary Outcomes
Incidence and rates of adverse events
Time Frame: Up to approximately 2 years
To assess the safety and tolerability of 7MW4911 in patients with advanced colorectal cancer and other advanced gastrointestinal tumors
Maximum tolerated dose (MTD), recommended expansion dose (RED) and the recommended phase II dose (RP2D)
Time Frame: Up to approximately 2 years
To determine the maximum tolerated dose (MTD) and recommended expansion dose (RED) or the recommended phase II dose (RP2D)
Secondary Outcomes
- Objective response rate(Up to approximately 2 years)
- Progression-free survival(Up to approximately 2 years)
- Immunogenicity(Up to approximately 2 years)
- Tmax(Up to 3 months)
- Cmax(Up to 3 months)
- t1/2(Up to 3 months)
- Area under the curve(Up to 3 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.NCT07258979MediLink Therapeutics (Suzhou) Co., Ltd.202
Recruiting
Phase 1
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT07260812TCRx Therapeutics Co.Ltd18
Recruiting
Phase 1
A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPCNCT07259213Radiopharm Theranostics, Ltd73
Recruiting
Phase 1
Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001Meningeal MetastasisNCT07264569Henan Cancer Hospital42
Recruiting
Phase 1
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced CancersNCT07260708Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.42